Original ContributionsPrimary and secondary cutaneous angiosarcoma: Distinctive clinical, pathological and molecular features
Introduction
Angiosarcomas (ASs) are a heterogenous group of malignant neoplasms characterized by endothelial differentiation [1]. ASs are ubiquitous neoplasms, involving both visceral and cutaneous and soft tissue locations. Rarely, they occur in association with other neoplasms [2]. Cutaneous angiosarcomas (cASs) are highly aggressive tumours arising in the skin, mainly seen in elderly patients with chronic solar damage, lymphedema or history of ionizing radiation [3]. Molecular findings in cASs partially differ from those occurring in visceral ASs. Despite several ongoing clinical trials with promising therapeutic agents, the prognosis of cASs is dismal and currently available treatment options are still limited. Consequently, an accurate and early diagnosis is essential for the best management of the patient. However, cASs are heterogeneous in terms of clinical presentation and histomorphology, and the differential diagnosis is wide, including benign vascular neoplasms, vascular tumours of uncertain malignant potential and high-grade neoplasms with differentiation other than endothelial.
This review aims to describe the biological, molecular, clinical and histolopathological features of cASs, with particular reference to the tools for correct recognition of these tumours and recently introduced diagnostic and prognostic factors.
Section snippets
Epidemiology and localizations
Cutaneous angiosarcoma (cAS) is a rare neoplasm with an incidence rate of about 0.5 new cases per 1,000,000 persons per year in the United States according to the Surveillance, Epidemiology, and End Results (SEER) Program database, accounting for less than 1% of all cutaneous sarcomas [4]. Currently the incidence rate seems to be increased in people over the age of 70 years, supposedly due to the relatively wide application of radiation-based therapies and the longstanding solar exposure in
Cutaneous AS molecular landscape: peculiarities with respect to visceral AS
Overall, the genetic profile of cAS is complex and not well defined, but the current knowledge suggests that ASs harbour biological differences by the site and that cAS may have biological peculiarities. The most commonly mutated genes in cAS include TP53, KRAS, PTPRB and PLCG1 [9]. Primary cAS frequently shows alterations of NTSR-1, ANKRD1 and CDKN2C, while upregulation of MYC, KIT, FLT4, RET, UNC5A, CTLA4, ISLR2, ICOS, RAB17, FLT4 and RASGRP3 has been reported in secondary cAS [10,11].
Primary versus secondary cASs: two different biomolecular profiles
The etiology and pathogenesis of cAS are still poorly understood. According to evidences accumulated during the last decades, two types of cAS can be defined on a pathogenetic basis: primary cAS, arising de-novo in a chronically sun-damaged skin, and secondary cAS, occurring mainly in a context of chronic lymphedema or in irradiated skin [3]. Although lymphedema and ionizing radiations are the most frequent and well-characterized clinical conditions associated with the development of secondary
Clinical findings and dermoscopy
Clinical features of cASs are extremely variable, since the neoplasm may mimic both other cutaneous neoplasms and non-neoplastic skin diseases. For example, cases of cASs clinically simulating rosacea, eczema, haemangioma, xanthelasma, cellulitis, and facial and eyelid angioedema, squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, atypical fibroxanthoma and malignant melanoma have been reported in literature [[27], [28], [29]]. However, at least in early stages, the most common
Histological findings
Histologically, cASs are quite heterogenous, depending on the degree of differentiation. Well-differentiated cASs display readily apparent vascular formation, while poorly differentiated cASs may show only limited – if any – morphological evidence of vascular differentiation. The diagnosis of cAS may be challenging, as well-differentiated forms can be hard to distinguish from benign and low-grade vascular neoplasms, while high-grade cASs can be easily confounded with other non-vascular poorly
Prognosis
cASs are aggressive neoplasms with poor outcome and high rate of metastases, mainly to lungs, bones, liver and lymph-nodes [49]. The reported 5-year survival rates ranged from 10% to 40% in the largest published series [49,50]. Tumour histologic grade does not seem to be a good predictor of prognosis in cASs [51]. On the other hand, adverse prognostic factors in cAS include age > 70 years, poor performance stadium, large tumour size (>5 cm), greater tumour depth, multifocality, presence of
References (63)
- et al.
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema
Am J Pathol
(2010) - et al.
Angiogenic growth factor expression in benign and malignant vascular tumours
Exp Mol Pathol
(2014) - et al.
Angiosarcoma in patients with xeroderma pigmentosum: less aggressive and not so rare?
J Am Acad Dermatol
(2013) - et al.
Abdominal wall angiosarcoma in a patient with drug-induced immunosuppression following renal transplantation
Actas Dermosifiliogr
(2016) - et al.
Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases
Mod Pathol
(2012) - et al.
MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study
Mod Pathol
(2014) - et al.
Dermoscopic pattern of radiation-induced angiosarcoma (RIA)
J Am Acad Dermatol
(2015) - et al.
Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas
Mod Pathol
(2002) - et al.
Angiosarcoma
Lancet Oncol
(2010) - et al.
Cutaneous angiosarcoma. Analysis of 434 cases from the surveillance, epidemiology, and end results program, 1973-2007
Ann Diagn Pathol
(2011)
Prognostic features in angiosarcoma of the head and neck: a retrospective monocenter study
J Craniomaxillofac Surg
Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack
Am J Pathol
WHO classification of tumours of soft tissue and bone
Epithelioid angiosarcoma arising in schwannoma of the kidney: report of the first case and review of the literature
World J Surg Oncol
WHO classification of skin tumours
Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases
Cancer
Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study
J Am Acad Dermatol.
Cutaneous versus non-cutaneous angiosarcoma: clinicopathologic features and treatment outcomes in 60 patients at a single Asian cancer centre
Oncology
Angiosarcoma of skin and soft tissue: a study of forty-four cases
Cancer
Vascular tumours in infants. Part II: vascular tumours of intermediate malignancy [corrected] and malignant tumours
Br J Dermatol
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway
Oncotarget
Key roles for MYC, KIT and RET signaling in secondary angiosarcomas
Br J Cancer
Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas
J Surg Oncol
Recurrent PTPRB and PLCG1 mutations in angiosarcoma
Nat Genet
Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas
Histopathology
Atypical presentation of angiosarcoma of the scalp in the setting of human immunodeficiency virus (HIV)
World J Surg Oncol
Angiosarcoma arising in an arteriovenous fistula in a patient without kidney transplant
Acta ChirBelg
Cutaneous angiosarcoma: a current update
J Clin Pathol
Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction
J Leukoc Biol
Reflecting on 25 years with MYC
Nat Rev Cancer
Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions
Genes Chromosomes Cancer
Cited by (11)
Current understanding of comparative pathology and prospective research approaches for canine hemangiosarcoma
2024, Research in Veterinary ScienceCutaneous angiosarcoma of head and neck: Case report and literature review
2023, Oral Oncology ReportsVascular Anomalies: Other Vascular Tumors
2022, Dermatologic ClinicsCitation Excerpt :Some case reports have noted a role of BRCA1 and BRCA2 mutations in predisposing affected patients to angiosarcoma following breast cancer treatment.187 Other mutations include TP53, overexpression of Wilms’ tumor-1 and galectin-3, HRAS activation, KRAS mutations, upregulation of KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), RET (Ret Proto-Oncogene), and numerous others.181,188 More recently, amplification and overexpression of MYC on chromosome 8 has been recognized in cutaneous, breast, and postradiation sarcoma.189–192
Differences in potential key genes and pathways between primary and radiation-associated angiosarcoma of the breast
2022, Translational OncologyCitation Excerpt :Primary angiosarcoma of the breast is a rare malignant tumor that occurs without a history of cancer or identifiable risk factors and usually occurs in women between the ages of 30 and 50 years [30]. Recently, multiple reports highlighted the increasing incidence in secondary breast angiosarcoma with the rise in the number of women with breast cancer treated with breast conservation therapy (BCT) and postoperative radiotherapy [22,30,31]. However, most current studies on primary and secondary angiosarcomas are case reports and little is known about the genetic abnormalities due to the lack of large-scale genomic studies, which seriously hinders the progress of diagnosis and treatment of angiosarcoma.
Hemoptoe, thin-walled lung cysts, and spontaneous pneumothorax are features of metastatic cutaneous angiosarcoma: A case report
2023, Wiener Medizinische Wochenschrift